Hamidreza Hozouri, Alireza Shamsian, M. Aghasadeghi, D. Doroud
{"title":"2015 - 2017年伊朗卫生部CDC与VAERS数据乙型肝炎疫苗AEFI比较研究","authors":"Hamidreza Hozouri, Alireza Shamsian, M. Aghasadeghi, D. Doroud","doi":"10.52547/vacres.8.1.52","DOIUrl":null,"url":null,"abstract":"of rHBV, with those in The The most common adverse after administration of rHBV, manufactured by Pasteur of Iran was injection site reactions and no life threatening adverse event was observed. Conclusion: Despite reports by VAERS indicating that HBV can cause adverse events and even death in the United States, no such adverse effects were observed in rHBV in","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017\",\"authors\":\"Hamidreza Hozouri, Alireza Shamsian, M. Aghasadeghi, D. Doroud\",\"doi\":\"10.52547/vacres.8.1.52\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"of rHBV, with those in The The most common adverse after administration of rHBV, manufactured by Pasteur of Iran was injection site reactions and no life threatening adverse event was observed. Conclusion: Despite reports by VAERS indicating that HBV can cause adverse events and even death in the United States, no such adverse effects were observed in rHBV in\",\"PeriodicalId\":52727,\"journal\":{\"name\":\"Vaccine Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52547/vacres.8.1.52\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52547/vacres.8.1.52","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017
of rHBV, with those in The The most common adverse after administration of rHBV, manufactured by Pasteur of Iran was injection site reactions and no life threatening adverse event was observed. Conclusion: Despite reports by VAERS indicating that HBV can cause adverse events and even death in the United States, no such adverse effects were observed in rHBV in